0107 ECP Myeloid Tx
BioCentury & Getty Images

Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Emerging Company Profile: Myeloid launches with programmed monocyte cell therapies for cancer

Myeloid launches with over $50 million from lead investor Newpath and monocyte cell therapies engineered to target cancer cells and coordinate antitumor immune functions.

Jan 8, 2021 | 2:46 AM GMT

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor

Read the full 764 word article

How to gain access

Continue reading with a
two-week free trial.